Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
JERUSALEM, Jan. 30, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ:ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that it will participate and be available for investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held February 13 – 14, 2024 in a virtual format.
Related news for (ENTX)
- Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
- 24/7 Market News Snapshot 28 July, 2025 – Entera Bio Ltd. Ordinary Shares (NASDAQ:ENTX)
- Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
- Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
- Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis – Highlighted as Oral Presentation at WCO-IOF ESCEO